New combo therapy shows promise for tough lung cancer

NCT ID NCT07425795

Recruiting now Disease control Sponsor: Chongqing University Cancer Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new treatment for people with extensive stage small cell lung cancer, a fast-growing cancer that has spread. Participants first get a drug called tislelizumab plus chemotherapy, then chest radiation if the cancer shrinks, followed by maintenance tislelizumab for up to 2 years. The goal is to see how long the cancer stays under control. About 36 newly diagnosed adults will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC)

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Chongqing University Affiliated Cancer Hospital
RECRUITING

Chongqing, Chongqing Municipality, 400000, China

Contact Phone: •••-•••-•••• Email: •••••@•••••